FOR RESEARCH PURPOSES ONLY — NOT FOR HUMAN USE. Clean Peptides does not provide advice on dosages or usage. This page compiles product information from Clean Peptides together with independent educational material from PeptideWiki, for research reference only. It is not medical advice and does not represent recommendations, endorsements, or instructions from Clean Peptides. Dosing here is derived from animal studies and community protocols — not human clinical trials.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in human gastric juice. It is unusually stable in stomach acid, allowing both injectable and oral administration. Its research interest centers on tissue-protective and regenerative properties — animal studies show accelerated healing of tendons, ligaments, muscles, nerves, the GI tract and bone. Mechanisms include upregulation of growth factors (VEGF, EGF), promotion of angiogenesis, and modulation of the nitric oxide system. Available as BPC-157 5mg and BPC-157 10mg vials.
Key Characteristics
- Pentadecapeptide — 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).
- Gastric juice-derived — stable in stomach acid, unusual for peptides.
- Multi-route — active by subcutaneous/intramuscular injection and orally.
- Tissue repair — tendons, ligaments, muscles, gut lining, nerves and bone in animal models.
- Angiogenesis — upregulates VEGF, promoting new blood vessel formation at injury sites.
- NO system modulation — influences blood flow, inflammation and tissue-repair signaling.
How Dosage Is Determined
Dosing (in micrograms) comes from animal studies, allometric scaling and extensive community experience. Rodent studies typically use 10 mcg/kg–10 mg/kg; a common rat dose of 10 mcg/kg scaled to a 75 kg human yields ~200–300 mcg. The 250 mcg once/twice daily protocol is the de facto community standard. Strength of evidence: low to moderate — large animal literature, minimal controlled human trials.
Standard Dosage Ranges
Subcutaneous / Intramuscular
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low / Starter | 150–200 mcg | Once daily | Minor injuries, general recovery |
| Standard | 250 mcg | Once or twice daily | Most common; tendon, ligament, muscle injuries |
| Aggressive | 300–500 mcg | Twice daily | Serious/post-surgical; diminishing returns above |
Oral
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Standard Oral | 500 mcg | Once daily, empty stomach | Gut healing — ulcers, IBS, inflammation |
| Higher Oral | 500–750 mcg | Split into 2 doses | Severe GI; 20–30 min before meals |
Weight-Based
| Body Weight | 2.5 mcg/kg | 3.3 mcg/kg | 5 mcg/kg |
|---|---|---|---|
| 60 kg | 150 mcg | 200 mcg | 300 mcg |
| 75 kg | 188 mcg | 250 mcg | 375 mcg |
| 90 kg | 225 mcg | 300 mcg | 450 mcg |
| 110 kg | 275 mcg | 363 mcg | 550 mcg |
Reconstitution & Dosing (with the supplied 3 mL)
Every Clean Peptides vial ships with 3 mL of bacteriostatic water (0.9% benzyl alcohol). All figures below assume you reconstitute with the full 3 mL. On a standard U-100 insulin syringe, 100 units = 1 mL.
Quick formula: concentration = vial strength ÷ 3 mL, and units to draw = dose (mg) × 300 ÷ vial strength (mg).
How to Reconstitute
- Wash your hands and lay out the vial, the 3 mL bacteriostatic water, an insulin syringe and alcohol swabs on a clean surface.
- Flip off the caps and swab both rubber stoppers with alcohol; let them air-dry 10–15 seconds.
- Draw the full 3 mL of bacteriostatic water (in three 1 mL passes with an insulin syringe, or in one pass with a 3 mL syringe).
- Add the water slowly, angling the needle so it runs down the inside glass wall — never squirt it directly onto the powder cake.
- Dissolve gently — let the vial sit 1–2 minutes, then swirl or roll it between your palms until the solution is clear. Never shake.
- Label and refrigerate at 2–8 °C. Resulting concentration: 5 mg → 1.67 mg/mL; 10 mg → 3.33 mg/mL.
Storage: unreconstituted powder refrigerated (2–8 °C); reconstituted solution refrigerated and used within 28–30 days; do not freeze; protect from light and heat.
Draw Volumes with 3 mL — BPC-157
Dosage by Goal
- Tendon & ligament injuries: 250–500 mcg/day SubQ, once/twice daily, near the injury; 4–8 weeks (up to 12 for chronic).
- Gut health & GI healing: 500–750 mcg/day oral preferred, empty stomach, 20–30 min before meals; 4–8 weeks.
- Joint pain & arthritis: 250–300 mcg/day SubQ near the joint; 4–8 weeks.
- Post-surgical recovery: 250–500 mcg twice daily near the site (once cleared by surgeon); 4–8 weeks.
- General recovery & wellness: 150–250 mcg/day SubQ abdominal; 4–6 weeks then break.
Consistency matters more than dose size — daily dosing for the full protocol outperforms sporadic higher doses.
Injection Guide
- Wash hands; prepare workspace.
- Swab the vial stopper; air-dry.
- Draw your dose; tap out bubbles.
- Choose site — local (near injury) for musculoskeletal issues; systemic (lower abdomen/thigh) otherwise.
- Clean the site; air-dry.
- Inject into a pinched fold at 45°.
- Dispose in a sharps container.
Inject subcutaneously near the injury — not into the tendon, ligament or joint capsule. IM injection (25–27 g, 90°) is an option for deep muscle. BPC-157 works both locally and systemically.
Cycle Duration & Timing
| Protocol | Duration | Notes |
|---|---|---|
| Standard cycle | 4–6 weeks | Acute/moderate injuries |
| Extended cycle | 8–12 weeks | Chronic tendinopathy, post-surgical |
| Repeat cycle | 4–6 wk on, 2–4 wk off, repeat | Stubborn/recurring injuries |
| Gut healing | 4–8 weeks (oral) | Reassess after one cycle |
Once daily (morning common) or twice daily split 8–12 h apart. Oral dosing on an empty stomach, 20–30 min before a meal. No strict timing requirement otherwise.
Stacking Protocols
BPC-157 + TB-500 (“Wolverine Stack”): localized repair + systemic healing.
| Compound | Dose | Frequency | Purpose |
|---|---|---|---|
| BPC-157 | 250 mcg SubQ | Once/twice daily (near injury) | Local repair, angiogenesis |
| TB-500 | 2–2.5 mg SubQ | 2x/week loading, 1x/week maintenance | Systemic anti-inflammatory |
See the separate TB-500 Dosage Guide for full TB-500 protocols. BPC-157 + GH secretagogues (Ipamorelin / CJC-1295): add systemic GH/IGF-1 support. GH secretagogues injected before bed, fasted 2–3 h; BPC-157 any time.
Safety, Side Effects & Contraindications
Exceptional animal safety profile — no lethal dose established in rodents. Human clinical data is extremely limited.
Common (mild, transient): nausea (more with oral), dizziness, injection-site redness/soreness, headache, fatigue. Rare: hot/cold flashes, blood-pressure changes.
Contraindications: active cancer or history of cancer (promotes angiogenesis); pregnancy and breastfeeding; active infection at the injection site; caution with anticoagulant therapy.
Interactions: NSAIDs (BPC-157 is gastro-protective in animals), blood thinners (NO system), dopaminergic drugs. Regulatory: not FDA-approved; research peptide; prohibited by WADA.
Common Mistakes
- Injecting directly into a tendon/ligament (inject SubQ near it).
- Over-diluting the vial (increases injection volume/discomfort).
- Not refrigerating reconstituted vials.
- Shaking the vial (denatures the peptide).
- Stopping too early after initial improvement.
- Using oral dosing for a musculoskeletal injury (oral is best for gut).
- Reusing syringes.
Key Takeaways
- 15-amino-acid peptide from gastric juice; researched for tissue repair.
- Standard dose 250 mcg SubQ once/twice daily; 500–750 mcg orally for gut healing.
- Inject near the injury for local repair; abdominal SubQ for systemic effect.
- Reconstitute with the supplied 3 mL. Typical cycle 4–8 weeks.
- Top stack: BPC-157 + TB-500. Store reconstituted vials refrigerated; use within 28–30 days.
- Not FDA-approved; banned by WADA.
Download & Related Resources
Shop BPC-157 5mg | Shop BPC-157 10mg
References
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157.” Curr Pharm Des. 2018;24(18):1990-2001.
- Seiwerth S, et al. “BPC 157’s effect on healing.” J Physiol Paris. 1997;91(3-5):173-178.
- Chang CH, et al. “BPC 157 enhances GH receptor expression in tendon fibroblasts.” Molecules. 2014;19(11):19066-19077.
- Staresinic M, et al. “BPC 157 accelerates healing of transected rat Achilles tendon.” J Orthop Res. 2003;21(6):976-983.
- Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157.” Curr Neuropharmacol. 2016;14(8):857-865.
© 2026 Clean Peptides. Educational reference compiled with independent material from PeptideWiki. For research purposes only — not for human use.
